ewsba.se
(RTTNews) - Bayer AG (BYR.L, BAYRY.PK, BAYZF.PK, BAY.MI, BAYN.DE), a German healthcare and agriculture conglomerate, on Wednesday, announced that it has agreed to acquire Perfuse Therapeutics Inc. for up to $2.45 billion to expand its ophthalmology pipeline.
The transaction includes an upfront payment of $300 million, along with additional development, regulatory, and commercial milestone payments.
The acquisition will give Bayer full rights to PER-001, a Phase II small molecule endothelin receptor antagonist being developed for the treatment of glaucoma and diabetic retinopathy.
The deal is subject to regulatory approvals and approval from Perfuse's stockholders.
PER-001 is an investigational endothelin receptor antagonist delivered via a bio-erodible intravitreal implant for sustained treatment of ophthalmic diseases such as glaucoma and diabetic retinopathy.
On Tuesday, Bayer closed trading 1.34% lesser at $37.90 on the XETRA.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This data feed is not available at this time.